第二波至疫情结束期间COVID-19患者体外膜氧合支持的院内结局与6个月随访结果(EuroECMO-COVID):一项前瞻性、国际、多中心、观察性研究
EuroECMO-COVID是一项前瞻性、国际、多中心、观察性研究,纳入21个国家98个中心、年龄≥16岁因COVID-19需要ECMO呼吸支持的成人患者3860例。院内死亡率为55.9%(2158例),其中81.2%(1752例)的死亡发生在ECMO支持期间。与院内死亡相关的因素包括年龄较大、ECMO前肾衰竭、ECMO前使用血管升压药、插管至ECMO启动时间较长,以及神经系统事件、脓毒症、肠缺血、肾衰竭和出血等并发症。1702例(44.1%)院内存活者中,99.7%(1697例)在6个月随访时仍存活;6个月随访时,1568例中有501例(32.0%)存在呼吸困难,122例(7.8%)有心脏症状,1567例中有168例(10.7%)有神经认知症状。作者认为,6个月出院后生存率良好,但出院后症状持续存在,确认需要ECMO后患者随访计划。
要点
- 纳入3860例COVID-19 ECMO患者,院内死亡率为55.9%(2158例),其中81.2%(1752例)的死亡发生在ECMO支持期间。
- 与院内死亡相关的因素包括年龄较大、ECMO前肾衰竭、ECMO前使用血管升压药、插管至ECMO启动时间较长,以及神经系统事件、脓毒症、肠缺血、肾衰竭和出血等并发症。
- 1702例(44.1%)院内存活者中,99.7%(1697例)在6个月随访时仍存活。
- 6个月随访时,1568例中有501例(32.0%)存在呼吸困难,122例(7.8%)有心脏症状,1567例中有168例(10.7%)有神经认知症状。
- 第二波疫情起院内死亡率高于初始疫情波,但出院后6个月生存率仍良好(99.7%)。
适用人群与场景
- 年龄≥16岁、因COVID-19需要ECMO呼吸支持的成人患者,来自21个国家98个中心。
- 研究时间为第二波疫情(2020年9月15日)至疫情结束(世界卫生组织宣布的2023年3月21日)。
研究设计与关键结果
- 研究类型:前瞻性、国际、多中心、观察性研究;纳入3860例患者(2687例[69.7%]男性,1169例[30.3%]女性;中位年龄51岁[SD 11]),来自21个国家98个中心。
- 院内死亡率为55.9%(2158例),其中81.2%(1752例)的死亡发生在ECMO支持期间;两组中位支持时间均为18天(IQR 10-31)。
- 与存活者相比,死亡者中糖尿病、高血压、心血管疾病和肾衰竭更多,且ECMO前需要更多正性肌力药和血管升压药。
- 与院内死亡相关的因素包括年龄较大、ECMO前肾衰竭、ECMO前使用血管升压药、插管至ECMO启动时间较长,以及神经系统事件、脓毒症、肠缺血、肾衰竭和出血等并发症。
- 1702例(44.1%)院内存活者中,99.7%(1697例)在6个月随访时仍存活。
- 6个月随访时,1568例中有501例(32.0%)存在呼吸困难,122例(7.8%)有心脏症状,1567例中有168例(10.7%)有神经认知症状。
证据类型、等级与局限
- 证据类型:前瞻性、国际、多中心、观察性研究(EuroECMO-COVID),注册号ClinicalTrials.gov NCT04366921。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,第二波疫情起COVID-19 ECMO患者院内死亡率高于初始疫情波,而出院后6个月生存率仍良好(99.7%)。
- 作者认为,出院后症状持续存在,确认需要ECMO后患者随访计划。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) for COVID-19 was thoroughly assessed during the first pandemic wave, but data on subsequent waves are limited. We aimed to investigate in-hospital and 6-month survival of patients with COVID-19 supported with ECMO from the second pandemic wave (Sept 15, 2020) until the end of the pandemic (March 21, 2023, announced by WHO).
METHODS: EuroECMO-COVID is a prospective, observational study including adults (aged ≥16 years) requiring ECMO respiratory support for COVID-19 from 98 centres in 21 countries. We compared patient characteristics and outcomes between in-hospital survivors and non-survivors. Mixed-effects multivariable logistic regressions were used to investigate factors linked to in-hospital mortality. 6-month survival and overall patient status were determined via patient contact or chart review. This study is registered with ClinicalTrials.gov, NCT04366921, and is complete.
FINDINGS: We included 3860 patients (2687 [69·7%] were male and 1169 [30·3%] were female; median age 51 years [SD 11]) from 98 centres in 21 countries. In-hospital mortality was 55·9% (n=2158), with 81·2% (n=1752) deaths occurring during ECMO support. More non-survivors had diabetes, hypertension, cardiovascular disease, and renal failure, and required more pre-ECMO inotropes and vasopressors compared with survivors. Median support duration was 18 days (IQR 10-31) for both groups. Factors linked to in-hospital mortality included older age, pre-ECMO renal failure, pre-ECMO vasopressors use, longer time from intubation to ECMO initiation, and complications, including neurological events, sepsis, bowel ischaemia, renal failure, and bleeding. Of the 1702 (44·1%) in-hospital survivors, 99·7% (n=1697) were alive at 6 months follow-up. Many patients at 6 months follow-up had dyspnoea (501 [32·0%] of 1568 patients), cardiac (122 [7·8%] of 1568 patients), or neurocognitive (168 [10·7%] of 1567 patients) symptoms.
INTERPRETATION: Our data for patients undergoing ECMO support for respiratory distress from the second COVID-19 wave onwards confirmed most findings from the first wave regarding patient characteristics and factors correlated to in-hospital mortality. Nevertheless, in-hospital mortality was higher than during the initial pandemic wave while 6-month post-discharge survival remained favourable (99·7%). Persisting post-discharge symptoms confirmed the need for post-ECMO patient follow-up programmes.
参考来源
- De Piero ME, Mariani S, van Bussel BCT, et al. In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study. Lancet Respir Med. 2025. PMID: 40010369. doi:10.1016/S2213-2600(24)00369-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。